Bluejay Diagnostics, Inc. (BJDX)
BJDXNASDAQ-CMMedical/Dental Instruments
$2.81
+0.3700 (+15.16%) today
At the close, Nov 10, 4:00 PM ET. After hours $2.69 -4.27%
- Market cap
- $3.14m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $2.43 to $2.90
- 52-week range
- $1.84 to $28.00
- Average volume
- 340.0k
- Previous close
- $2.44
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.62m | -$1.46m | -$1.94m | -$2.35m |
| Net income | -$1.60m | -$1.43m | -$1.92m | -$2.32m |
News
8 latest- Bluejay Diagnostics, Inc. Announces 1-for-4 Reverse Stock SplitFintel · 6 days ago
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials RTTNews · Sep 11, 2026
- 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara RTTNews · Sep 8, 2026
- Bluejay Diagnostics, Lovell Team Up To Access U.S. Federal Healthcare Market RTTNews · Sep 8, 2026
- Bluejay Reports Q2 2026 Results; Cash Position Strengthened Ahead Of Symphony IL-6 FDA Filing RTTNews · Aug 13, 2026
- Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High RTTNews · Aug 5, 2026
- Bluejay Completes Enrollment In SYMON-II Sepsis Study RTTNews · Jul 21, 2026
- Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN RTTNews · Jun 5, 2026
The company
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- bluejaydx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.